Literature DB >> 10024307

Induction of serotonin transporter by hypoxia in pulmonary vascular smooth muscle cells. Relationship with the mitogenic action of serotonin.

S Eddahibi1, V Fabre, C Boni, M P Martres, B Raffestin, M Hamon, S Adnot.   

Abstract

-The increased delivery of serotonin (5-hydroxytryptamine, 5-HT) to the lung aggravates the development of hypoxia-induced pulmonary hypertension in rats, possibly through stimulation of the proliferation of pulmonary artery smooth muscle cells (PA-SMCs). In cultured rat PA-SMCs, 5-HT (10(-8) to 10(-6) mol/L) induced DNA synthesis and potentiated the mitogenic effect of platelet-derived growth factor-BB (10 ng/mL). This effect was dependent on the 5-HT transporter (5-HTT), since it was prevented by the 5-HTT inhibitors fluoxetine (10(-6) mol/L) and paroxetine (10(-7) mol/L), but it was unaltered by ketanserin (10(-6) mol/L), a 5-HT2A receptor antagonist. In PA-SMCs exposed to hypoxia, the levels of 5-HTT mRNA (measured by competitive reverse transcriptase-polymerase chain reaction) increased by 240% within 2 hours, followed by a 3-fold increase in the uptake of [3H]5-HT at 24 hours. Cotransfection of the cells with a construct of human 5-HTT promoter-luciferase gene reporter and of pCMV-beta-galactosidase gene allowed the demonstration that exposure of cells to hypoxia produced a 5.5-fold increase in luciferase activity, with no change in beta-galactosidase activity. The increased expression of 5-HTT in hypoxic cells was associated with a greater mitogenic response to 5-HT (10(-8) to 10(-6) mol/L) in the absence as well as in the presence of platelet-derived growth factor-BB. 5-HTT expression assessed by quantitative reverse transcriptase-polymerase chain reaction and in situ hybridization in the lungs was found to predominate in the media of pulmonary artery, in which a marked increase was noted in rats that had been exposed to hypoxia for 15 days. These data show that in vitro and in vivo exposure to hypoxia induces, via a transcriptional mechanism, 5-HTT expression in PA-SMCs, and that this effect contributes to the stimulatory action of 5-HT on PA-SMC proliferation. In vivo expression of 5-HTT by PA-SMC may play a key role in serotonin-mediated pulmonary vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10024307     DOI: 10.1161/01.res.84.3.329

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  40 in total

1.  A role for the serotonin transporter in hypoxia-induced pulmonary hypertension.

Authors:  B L Fanburg; S L Lee
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

Review 2.  Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension.

Authors:  M Rabinovitch
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 3.  5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension.

Authors:  M R MacLean; P Herve; S Eddahibi; S Adnot
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

4.  Idiopathic pulmonary arterial hypertension: an avian model for plexogenic arteriopathy and serotonergic vasoconstriction.

Authors:  Robert F Wideman; Krishna R Hamal
Journal:  J Pharmacol Toxicol Methods       Date:  2011-01-26       Impact factor: 1.950

5.  Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells.

Authors:  Wenying Ren; Stephanie W Watts; Barry L Fanburg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-12-24       Impact factor: 5.464

Review 6.  One hundred years of research in the pathogenesis of pulmonary hypertension.

Authors:  Ari Zaiman; Iwona Fijalkowska; Paul M Hassoun; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2005-11       Impact factor: 6.914

7.  Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension.

Authors:  S Eddahibi; M Humbert; E Fadel; B Raffestin; M Darmon; F Capron; G Simonneau; P Dartevelle; M Hamon; S Adnot
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

Review 8.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01

9.  Platelet serotonin promotes the recruitment of neutrophils to sites of acute inflammation in mice.

Authors:  Daniel Duerschmied; Georgette L Suidan; Melanie Demers; Nadine Herr; Carla Carbo; Alexander Brill; Stephen M Cifuni; Maximilian Mauler; Sanja Cicko; Michael Bader; Marco Idzko; Christoph Bode; Denisa D Wagner
Journal:  Blood       Date:  2012-12-12       Impact factor: 22.113

Review 10.  How the serotonin story is being rewritten by new gene-based discoveries principally related to SLC6A4, the serotonin transporter gene, which functions to influence all cellular serotonin systems.

Authors:  Dennis L Murphy; Meredith A Fox; Kiara R Timpano; Pablo R Moya; Renee Ren-Patterson; Anne M Andrews; Andrew Holmes; Klaus-Peter Lesch; Jens R Wendland
Journal:  Neuropharmacology       Date:  2008-09-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.